The prevalence of digestive diseases has a significant impact in the United States, with more than 60 million Americans diagnosed each year. These conditions lead to more hospitalizations than any other disease state and represent the third-highest economic loss of all illnesses. Given the complexity of digestive diseases and the subtle presentation of symptoms, early and accurate detection is essential.1
When the American Cancer Society lowered its colorectal cancer screening age guideline from 50 to 45 for average-risk patients, an estimated 21 million people in the U.S. became newly eligible for screenings. Options include visual exams, such as a colonoscopy, and stool-based tests. Stool-based screenings are required more frequently than visual exams and should always be followed by a colonoscopy if results are abnormal.